Fast-Track Merger of a Wholly Owned Subsidiary with a Dissenting Minority
Apex Engineering Ltd holds 94% of Zenith Fabrication Ltd, acquired in two tranches over three years. Apex proposes a fast-track merger of Zenith into itself. Zenith's remaining 6% is held by 40 shareholders, of whom 12 acquired their shares after the first tranche was announced. The scheme values Zenith at a 15% discount to its last independent valuation, and the appointed date is 1 April, nine months before the scheme is filed. Zenith has an unsecured loan of INR 5 crore from a bank with a change-of-control clause, and one supplier has filed a recovery suit for INR 80 lakh. Apex's board approves the scheme and files it with the regulator without a shareholders' meeting, relying on the 90% threshold.
1. Can Apex use the fast-track route on these facts? Identify each eligibility hurdle and whether it is met.
Read the worked answer
The fast-track route is available only where the transferee holds at least 90% of the equity shares of the transferor. Apex holds 94%, so the numerical threshold is met. But eligibility is cumulative:
- Shareholding. 94% satisfies the 90% test; the 12 later acquirers do not dilute the holding, though their acquisition timing is relevant to any minority-oppression argument.
- Consent of the transferor company. The merger must be approved by the board of the transferor and by holders of at least 90% of the shares, or by a majority of the minority where the parent holds 90% or more. Apex cannot simply rely on its own board; Zenith's board must approve, and the minority must be given a vote.
- No regulatory bar. The scheme must not be subject to proceedings under the insolvency law, and the companies must be in compliance with statutory filings.
- Notice and objections. The regulator must be notified, and objections from the minority, the bank, and the supplier must be addressed before sanction.
The filing without a Zenith board resolution or minority vote is a fatal defect. The discount to valuation and the stale appointed date compound the problem: the appointed date cannot precede the filing by more than the period the regulator permits without explanation, and a 15% discount invites a valuation challenge.
2. How should the bank's change-of-control clause and the supplier's suit be handled before sanction?
Read the worked answer
Both are creditor-protection issues, and the scheme must show they are addressed.
- Bank loan. A change-of-control clause typically gives the lender a right to demand repayment or renegotiate. The scheme should disclose the clause, obtain the bank's written consent or a no-objection, or provide for the loan to be taken over by Apex on the same terms. Silence is not enough: the sanctioning authority will ask for the creditor's consent, and the bank can otherwise object.
- Supplier suit. A pending recovery suit does not bar a merger, but the scheme must disclose it and provide for the liability to vest in Apex as the transferee. A provision in the scheme transferring all liabilities, including contingent ones, and an undertaking to satisfy any decree is the standard fix.
- Minority protection. Where the parent holds 90% or more, dissenting shareholders must be offered an exit on a fair-value basis; the 15% discount is difficult to defend and should be renegotiated or explained by an independent valuer.
- Sequence. Obtain Zenith board approval, minority consent, bank consent, and a revised valuation before refiling. The appointed date should be moved to a defensible date, typically the start of the financial year in which the filing is made.